eli lilly glp 1 agonist is now pharma's top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn't celebrating Orforglipron: Eli Lilly's New Oral

Description

Whether and how GLP-1 medicines might impact the risk of cancer or infections when used in combination with other immunomodulatory treatments is not known

For researchers serious about optimizing their weight management protocols, SeekPeptides offers the most comprehensive resource available, with evidence-based guides, detailed dosing charts , calculators , and a community of thousands who have navigated these exact transitions

As the SELECT trial nears completion, a similar large trial was launched in autumn 2022, but this one involves a new wrinkle on GLP-1 receptor agonism that appears to yield even greater weight loss